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Abstract
Background: Since the launch of the Global Polio Eradication Initiative, all but three countries (Nigeria, Pakistan,
and Afghanistan) have apparently interrupted all wild poliovirus (WPV) transmission, and only one of three wild
serotypes has been reported globally since 2012. Countrywide supplemental immunization campaigns in Nigeria
produced dramatic reduction in WPV Type 1 paralysis cases since 2010 compared to the 2000’s, and WPV1 has
not been observed in Nigeria since July 24, 2014. This article presents the development and calibration of a
spatial metapopulation model of wild poliovirus Type 1 transmission in Kano State, Nigeria, which was the
location of the most recent WPV1 case and 5 out of 6 of the reported WPV1 paralytic cases in Nigeria in 2014.
Methods: The model is calibrated to data on the case counts and age at onset of paralysis from 2003–2009. The
features of the data drive model development from a simple susceptible-exposed-infective-recovered (SEIR) model to
a spatial metapopulation model featuring seasonal forcing and age-dependent transmission. The calibrated parameter
space is then resampled, projected forward, and compared to more recent case counts to estimate the probability that
Type 1 poliovirus has been eliminated in Kano state.
Results: The model indicates a 91 % probability that Type 1 poliovirus has been eliminated from Kano state
as of October 2015. This probability rises to >99 % if no WPV1 paralysis cases are detected for another year.
The other states in Nigeria have experienced even longer case-free periods (the only other state with a WPV1
case was Yobe, on April 19, 2014), and Nigeria is the last remaining country in Africa to experience endemic
WPV1 transmission, so these results can be interpreted as an upper bound on the probability that WPV1 transmission is
currently interrupted continent-wide.
Conclusions: While the results indicate optimism that WPV1 transmission has been interrupted in Kano state, the
model also assumes that frequent SIAs with high coverage continue to take place in Kano state through the end of the
certification period. We conclude that though WPV1 appears to be on the brink of continent-wide elimination (WHO
officially removed Nigeria from the list of polio-endemic countries on September 25, 2015), it is important for the polio
program to maintain vigilance in surveillance and vaccination activities to prevent WPV1 resurgence through the
WHO’s 3-year eradication certification period.
Abbreviations: AFP, Acute flaccid paralysis; bOPV, Bivalent oral polio vaccine; GPEI, Global polio eradication initiative;
IMIS, Incremental mixture importance sampling; IPV, Inactivated polio vaccine; LGA, Local governmental area; mOPV#,
Monovalent oral polio vaccine type #; OPV, Oral polio vaccine; RI, Routine immunization; SEIR, Susceptible-exposed-
infective-recovered; SIA, Supplemental immunization activity; tOPV, Trivalent oral polio vaccine; WHO, World health
organization; WPV#, Wild polio virus type # (1/2/3).
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Background
In 1988, the Global Polio Eradication Initiative (GPEI)
was launched, and since then, all but three countries
(Nigeria, Pakistan, and Afghanistan) have interrupted
endemic transmission of all three wild poliovirus (WPV)
serotypes [1]. The world has been free of WPV serotype
2 (WPV2) since 1999 [2], and no cases of WPV3 have
been reported since 2012 [1]. WPV1 transmission con-
tinues uninterrupted in Pakistan and Afghanistan, but
the last case in Nigeria was observed on July 24, 2014
[3]. WPV1 paralysis case counts in Nigeria in 2010–2014
were substantially lower than during the 2000s, and this
decline in cases has culminated in the announcement, on
25 September, 2015 [4], of the interruption of endemic
WPV1 transmission in Nigeria.
This article describes a polio transmission model de-
veloped to investigate the interruption of WPV1 trans-
mission in northern Nigeria. This question has been
addressed [5–8] using other transmission models; of
these, the models presented in [5, 8] are not calibrated
specifically to the Nigerian context, and indicate that
high (>95 %) confidence in WPV1 interruption may re-
quire case-free periods of 3 years or more, while [6, 7]
present models specific to northern Nigeria, and find
that as little as 1 year without a WPV1 paralysis case is
sufficient to be confident that transmission has been
interrupted. The model presented here is structurally
distinct from the models of [6, 7], and provides further
support for their conclusions that interruption can be
confidently declared with a shorter case-free period. The
model is calibrated to WPV1 case counts in Kano state,
Nigeria. Historically, Kano state accounts for approxi-
mately 30 % of WPV1 paralytic cases in northern
Nigeria (despite having only ~16 % of the total popula-
tion), and 5 of the 6 cases reported in 2014 were from
Kano state. The model is an individual-based model fea-
turing generic susceptible-exposed-infective-recovered
(SEIR) dynamics. The model was developed in a data-
driven iterative fashion, beginning with a homogenously
mixed, single-population SEIR model, to which age
structure, seasonal forcing, and spatial transmission are
progressively added to improve the ability of the model
to reproduce the observed historical data.
Methods
The generic disease branch of the individual-based dis-
ease modeling software EMOD DTK v1.6 was used to
model polio transmission. The model was developed in
an iterative fashion, beginning with a generic, individual-
based SEIR model, with age structure, seasonal forcing,
and division into spatial metapopulations progressively
added to the model to improve fits to the data. Only
children under 5 years of age are included in the model,
as these children account for ~98 % of total WPV1
paralytic cases in the dataset for northern Nigeria. The
2006 Nigerian census reports that 1.8 million children
under 5 years old lived in Kano state at that time [9].
The simulated birth rate maintains a population growth
rate of 2.8 % [10]. Our simulated population consists of
approximately 800 k agents in 2006 (averaged over
simulation instances, as vital dynamics are stochastic in
this model), so that each simulated individual represents
approximately 2.2 real individuals. Simulation with 1.8
million agents resulted in unacceptably long instance
runtimes. Reducing the simulated population prevented
this issue from occurring, and as the model implements
frequency-dependent transmission, the mean dynamics
should not directly depend on the number of simulated
agents, as long as that number is well above the critical
community size.
Upon clearance of infection or a successful immunization
with oral polio vaccine (OPV), individuals are modeled as
being completely immune to future infection. Challenge
studies have shown that individuals are in fact susceptible
to reinfection. However, the probability of reinfection is
strongly reduced after a successful infection or vaccination;
the metastudy presented in [11] estimates that the relative
odds of shedding serotype 1 poliovirus post-challenge
among OPV-vaccinated individuals compared with unvac-
cinated individuals is 0.13. [12] presents an odds ratio of
0.15, with 80 % of unvaccinated individuals excreting virus
post-challenge, compared with 37 % of OPV-vaccinated in-
dividuals. The OPV-vaccinated individuals in [12] were also
observed to shed for a mean of 4.6 days, as opposed to
20.4 days among the unvaccinated, and the mean titer of
virus excreted by OPV-vaccinated individuals was over 3
orders of magnitude lower than unvaccinated controls; nat-
urally immune individuals exhibited similar characteristics
to the OPV-vaccinated group. The reduced chance of
infection, shorter shedding period, and reduced shed-
ding titer of OPV- and WPV-experienced individuals
combine to provide support to the simplifying assump-
tion that the observed disease transmission dynamics
are driven primarily by naïve individuals, rather than by
reinfection of previously individuals.
The historical SIA campaign calendar for northern
Nigeria (see Fig. 8) is implemented in simulation. In cali-
bration of this model, the effects of SIA campaigns are
parametrized by a campaign coverage multiplied by as-
sumed vaccine take rates for different vaccine types. The
product of the two represents the fraction of susceptible
children immunized in a single SIA round and is the
relevant quantity being calibrated; this product is con-
strained to lie between 0 and 1. Model calibration figures
will present the campaign coverage alone, as the vaccine
take rates are assumed to be constant. Trivalent OPV
campaigns are modeled with a 15 % probability of suc-
cessful vaccination against type 1, while monovalent
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OPV1 and bivalent OPV are modeled with a 20 %
success probability each; these numbers are taken
from 30-day seroconversion rates to a birth dose in
India [13]. The efficacy of the multiple types of OPV
has been measured in numerous studies [11, 13–22], and
the results vary considerably across studies. The numbers
employed here are on the lower end of observed single-
dose take rates. Circulation of attenuated vaccine-derived
virus is not modeled. Each simulation begins on Jan 1,
1985, with a 5-year period in which infected individuals
are stochastically imported into the network. The mean
importation rate is one infected individual per week per
10 k population for these 5 years, after which the disease
is sufficiently established to survive without importation
in the absence of vaccination. The SIA campaign calendar
was provided by the Nigerian WHO and [23–26].
Model development and calibration
The acute flaccid paralysis (AFP) surveillance database,
maintained by the Nigerian WHO, provides the basis for
model calibration; the model was calibrated only to data
from 2003–2009. Only AFP cases with WPV1 shedding
confirmed by the Global Polio Laboratory Network [27]
are included. Incremental mixture importance sampling
(IMIS) [28] was used for parameter space exploration
and calibration. Though IMIS applies to deterministic
models and true likelihood functions, the authors find it
to work quite well at calibrating stochastic models given
an objective function, so long as parameter-based vari-
ation in the objective function outweighs the stochastic
variance in the objective function at a particular param-
eter set, as is the case for most of the calibrations pre-
sented below. The value of the objective functions
evaluated at a particular parameter set and stochastic
instance will be referred to as the score. The objective
functions themselves are described in detail in Additional
file 1. The data targets are the time series of case counts,
binned twice per month; the distribution of age at onset of
paralysis, binned into 6-month age bins; and the spatial
distribution of cases at the LGA level.
The model was developed in an iterative fashion, be-
ginning with a generic, individual-based SEIR model,
and adding age structure, seasonal forcing, and division
into spatial metapopulations progressively to improve
fits and target additional features of the data. The model
development and calibration section is split into subsec-
tions describing the reasoning and calibration at each
step of development, beginning with a very simple (and
poor) model and progressing through a couple of inter-
mediate models before arriving at the finalized model.
The reader may wish only to see the specification and
calibration of the finalized model and results, contained
in Additional file 1– Model Specification, Model Devel-
opment – Spatial Model, and Results, respectively.
Model development – Basic SEIR model
The incubation and infectious periods, base reproductive
number, and the campaign coverage of a basic SEIR
model were fit to these data. Campaign coverage is as-
sumed to be constant over this time period, and cam-
paigns are modeled as being randomly accessed by
individuals, with no structured heterogeneity in individ-
uals’ probabilities of being vaccinated in a single cam-
paign. The infectious and incubation periods are of fixed
duration, rather than exponentially distributed. The
choice of a fixed duration maintains the benefit of hav-
ing only a single parameter to calibrate for each, like the
exponential distribution, while removing that distribu-
tion’s probability of individuals drawing unrealistically
short infectious durations.
The case-to-infection ratio of WPV1 in immunologic-
ally naïve individuals is approximately 1:200 [29]. For
the purposes of calibration, the modeled incidence over
time is fit to the case count data using a Poisson ap-
proximation to a binomial objective function, which is
maximized over an unconstrained case-to-infection ratio
(for an investigation of overdispersion in the case counts
relative to the model, and how this affects the results,
please see Additional file 1, Overdispersion section).
This construction provides a scale-independent fit of the
shape of the modeled incidence curves to the case
counts over time. In the high-incidence periods used for
calibration and with a large simulated population, the
average dynamics are quite insensitive to the total mod-
eled population. More details about the objective func-
tions employed are included in Additional file 1.
Figure 1 presents the results of this calibration.
Figure 1(a) and (b) show that the objective score is
strongly dependent on R0 and SIA coverage, but relatively
weakly dependent on the incubation and infectious
periods; the space around 4 days exposed and 5 days
infectious is preferred, but individual samples of com-
parably high score are present throughout the 2D
space. Figure 1(c) and (d) present the target data as
blue bars. The red contours indicate the 68 %/95 %/
99 % quantiles of distributions constructed by weighting
the outputs according to their score (were the objective
functions true likelihoods, these would represent quantiles
of the posterior distribution; as they are not, the statistical
interpretation of these contours is not immediately ob-
vious, but they serve to demonstrate how well the cali-
brated model reproduces the targeted features of the
data). These figures demonstrate that the capability of
this model to fit the data is rather poor; the age distri-
bution of infection (as expected) is monotonically de-
creasing, in contrast to the data which peaks in the
1.5–2 year age bin. The simulated case counts over
time do exhibit a low-amplitude oscillation with the 2-
year periodicity exhibited by the data, but fail to
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reproduce the high amplitude of the outbreaks and long
troughs of very low case counts in the data.
Model development – Age dependent exposure and
seasonality
The poor performance of a basic SEIR model is not un-
expected. In a homogenously mixed SEIR model, new
infections will be distributed uniformly among the sus-
ceptible population, the proportion of susceptibles will
decline with age as older age groups have been exposed
for longer, and the distribution of new infections will
thus decline with age as well, as seen in the simulation
results of Fig. 1(a). Similarly, oscillatory behavior in a
homogenously-mixed SEIR models is expected to damp
toward an equilibrium value; stochastic resonance can
drive oscillations at the natural frequency of the system,
but for the large population simulated here these oscilla-
tions are insufficiently large to explain the data. This
model is presented primarily for comparison against
more developed models, to demonstrate the value of
additional data-driven complexity.
A number of mechanisms could potentially explain
the discrepancy in the simulated age at infection dis-
tribution and the observed age at onset of paralysis.
Age-dependence in the case-to-infection ratio has
been reported in the past [30]; however, the measure-
ments indicate no more than a factor of 2 difference
over the first 5 years of life, insufficient to transform
the simulated distribution into the data. Maternal
antibodies are another obvious potential explanation,
but previous work indicates that these wane with a
half-life on the order of 3–4 weeks [31–35], much
too rapidly to solely explain a rising attack rate over the
first 2 years of life. The hypothesis implemented into the
model is reduced mixing by young children, such that the
force of infection is reduced by an age-dependent factor.
For simplicity’s sake, this age-dependent scaling factor is
assumed to be multiplicative, linearly dependent on age,
and bounded between 0 and 1 (where 0 represents no ex-
posure to infectivity, and 1 represents full exposure. To
clarify, let β(a, t) represent the force of infection from all
infectives onto susceptibles of age a, then:
β a; tð Þ ¼
0; f 0 þ f 1a≤0
β0 f 0 þ f 1að Þ; 0 < f 0 þ f 1a < 1
β0; f 0 þ f 1a≥1
8<
:
The model is recalibrated, with the slope and age-0
intercept of this scaling factor included as additional di-
mensions in the calibration.
Figure 2 shows the results of this calibration. The sim-
ulated age at infection distribution depends most
strongly on the base reproductive number and the slope
and intercept of the age-dependent mixing coefficient.
Figure 2 only presents the score in the 2D space of R0
and the slope of the age-dependent mixing; the most
likely points for the intercept are clustered near 0, as ex-
pected due to the very low case counts in the 0–6
month age bin. It should be noted that this reduced mix-
ing induces a shift in the true R0 that depends on the
age-dependent mixing factor and the age distribution of
the population; for the remainder of this paper, R0 (or
base reproductive number in figure axes) will refer to
a b
c d
Fig. 1 Calibration of basic SEIR model. a Log-score (color) vs. incubation and infectious period. b Log-score vs. R0 and campaign coverage.
c Data (blue) and score-weighted distribution of simulations (68, 95, 99 % quantiles in red) for age distribution of paralysis cases. d Data (blue)
and score-weighted distribution of simulations (68, 95, 99 % quantiles in red) for time series of case counts
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the daily force of infection times the infectious period,
which represents the R0 within a fully mixed population.
For subsequent calibrations and model runs, the inter-
cept of age-dependent mixing will be fixed at 0 (see Fig. 2
panel b), and the relationship between the slope and the
base reproductive number will used to collapse these two
onto a single dimension; that is, R0 will remain a freely fit-
ted parameter, but at a given R0, the age-dependent mixing
slope is determined by the fitted curve shown in Fig. 2a.
The next model iteration aims to address the strong
periodicity and high amplitude of WPV1 outbreaks, by
adding a seasonal forcing term to the infectivity:
β→β 1þ A cos t−t0
365
   
Seasonal outbreaks have been observed in many infec-
tious diseases [36–43], and seasonally-forced models
have been shown to exhibit bifurcations from annual
outbreaks to dynamics with longer periodicities [44, 45].
The 2-year periodicity of WPV1 outbreaks in Kano state
constrains the space of combinations of base reproduct-
ive number, SIA campaign coverage, and seasonal for-
cing amplitude.
Figure 3 shows the results of this calibration procedure.
The fit to the case count data is substantially improved by
the addition of seasonal forcing to the model, and the fit
to the age distribution remains good. The overall peak
score has increased dramatically; compare the color bar
limits between Fig. 3 and Fig. 1. The structure of the ob-
jective function presents some interesting features, with
multiple broad regions of high score. The incubation
period and infectious period are not strongly constrained
by the fits, but existing studies indicate a very short delay
from exposure to the onset of viral excretion [46, 47].
When the calibration space is restricted to include only
incubation periods between 1 and 5 days, the score-
weighted mean infectious period is 27 days, a value which
is also within the range supported by shedding studies
[12, 46, 48]. Inclusion of these features appears to
have improved the fit of these biological parameters rela-
tive to the SEIR model without these additional features,
which inferred a mean infectious period of only a few days,
Fig. 1. The seasonal forcing model is best fit with an ampli-
tude of 0.11 and a peak on April 10. These values will be
fixed in future calibration runs, while R0 and the mean SIA
campaign coverage remain as calibration parameters.
As noted early in this section, the time series of cases
from data and infections from simulation are compared
using a scale-independent fit, with the case-to-infection
ratio representing a free scaling parameter in the fit.
While this simple SEIR model with minimal added com-
plexity is able to reproduce the outbreak dynamics, the
weighted mean case-to-infection ratio is about 1:1650,
much lower than the expected 1:200 ratio for WPV1.
Assuming the expected 1:200 ratio, the model overpre-
dicts the observed number of cases by a factor of ap-
proximately 8 on average. This discrepancy may indicate
the existence of some unmodeled complexities. Multiple
hypotheses could all plausibly contribute to this discrep-
ancy: The assumption of complete immunity after infec-
tion with OPV or WPV rather than the biologically
justifiable partial immunity and waning immunity could
allow for some degree of transmission to proceed
through individuals who are less likely to present
Fig. 2 Calibration of SEIR model w age-dependent transmission. a Log-score (color) vs. base infectivity and the slope of age-dependent susceptibility
in early life (described in text). b Log-score (color) vs. the age-0 intercept and slope of age-dependent susceptibility in early life. c Data (blue) and
score-weighted distribution of simulations (68, 95, 99 % quantiles in red) for age distribution of paralysis cases
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paralysis (though for reasons given previously, the au-
thors expect this contribution to transmission to be
small), individual-level heterogeneity in transmission
(through host factors or disparate social networks), and
the treatment of Kano as a single mixing population, ra-
ther than accounting for the spatial distribution of the
population and how this affects transmission. The model
development proceeds by investigating this last hypoth-
esis, though all are likely to contribute.
Model development – Spatial model
The polio case dataset used for calibration reports cases
at the scale of local government areas (LGAs), providing
spatial information that may also be incorporated into
model calibration, which requires splitting the single-
population model presented above into a set of meta-
populations. Construction of the spatial metapopulation
model is covered in detail in Additional file 1. WorldPop
[49, 50] population maps are the basis for metapopula-
tion construction. Spatially contiguous features of high
population density are identified and aggregated into
population centers, with the total population placed at
the population-weighted mean latitude and longitude.
Any remaining low-density background population is ag-
gregated to the nearest population center. Nodes with
total populations below 1000 individuals are merged
with their nearest neighbor. This process results in 1322
nodes. Each of these population centers is a separate
metapopulation, or node, in the model.
Nodes are internally well-mixed (with the age-
dependent mixing described above), and coupled to each
other through migration of individuals. Individuals are
assumed to take only round-trip migration, with an aver-
age duration of 1 day at the destination node. Individual
migration rates are assumed to follow a gravity-like
model, with the rate linearly increasing with destination
population, inversely linear with the distance to the des-
tination node, and independent of the population of the
home node.
Rij ¼ A 
pj
dij
The migration rate is implemented in units of per-
individual per day, so that the total flow from node i to
node j is implicitly linear in the population of node i.
The network is not completely connected; migration
from a node only occurs to its 8 nearest nodes and its
30 remaining most probable destinations.
Fig. 3 Calibration of SEIR model w age-dependent transmission and seasonal forcing. a Log-score (color) vs. incubation and infectious periods.
b Log-score vs. R0 and campaign coverage. c Log-score (color) vs. the phase and amplitude of seasonal forcing in infectivity. d Data (blue) and
score-weighted distribution of simulations (68, 95, 99 % quantiles in red) for age distribution of paralysis cases. e Data (blue) and score-weighted
distribution of simulations (68, 95, 99 % quantiles in red) for time series of case counts
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Calibration of the spatial model covers a 5-dimensional
parameter space including the coverages of routine
immunization (RI) and campaign immunization, the base
reproductive number, a coefficient of variation in cam-
paign coverage (though not RI) at the LGA level, and the
scaling constant of the overall rate of migration.
The spatial parameters added to the model necessitate
the addition of components to the objective function
that are sensitive to spatial effects. The new target data
include the number of LGAs reporting at least one case
within a 3 month time window, and the annual case
counts in each of the 44 LGAs of Kano state. The ob-
jective functions do not aim to match specific LGAs be-
tween simulation and data, but target the general
heterogeneity in LGA-level case counts.
Results of the calibration are presented in Fig. 4 (except
for the age of infection distribution, suppressed as the fit
is of similar quality to those presented previously). Panels
a-c present the log-score distributions in 2D planes similar
to those shown previously. The best-fit campaign and RI
coverages both increase with infectivity, as expected. The
LGA-level coefficient of variation of the campaign cover-
age is not strongly constrained, though the scaling factor
on the migration rate is constrained to lie within ap-
proximately 1 order of magnitude. To provide an inter-
pretation for this result, Fig. 5 presents a histogram of
the unscaled migration rates by node. Scaling this
histogram by the high-score region in Fig. 4(c) reveals
that the best fits occur when individuals in most nodes
have outbound travel frequencies from about once per
3 days to once per 30 days.
The inferred case-to-infection ratio from the metapopu-
lation model was approximately 1:1200. While still much
higher than the expected 1:200, this does represent an im-
provement in the overall scale of the simulated outbreaks
when compared with the single-population model. Other
unmodeled heterogeneities may be responsible for the
continuing discrepancy; perhaps the modeled population
may be viewed as an undervaccinated subpopulation or a
subpopulation at high risk relative to the total population.
After calibration of the spatial model, the model is ap-
plied to the question of elimination. At the time of writ-
ing, no cases of WPV1 paralysis have been observed in
Nigeria since July 24, 2014. The WHO standard for cer-
tifying interruption of WPV in a region is 3 years with-
out an observed paralysis case. Other models have been
Fig. 4 Calibration of the spatial polio-like model. a Log-score (color) vs. R0 and campaign coverage. b Log-score (color) vs. R0 and RI coverage.
c Log-score (color) vs. scaling term in the migration model (x) and LGA-level coefficient of variation in campaign coverage. d Data (blue) and
score-weighted distribution of simulations (68, 95, 99 % quantiles in red) for time series of case counts. e Data (blue) and score-weighted distribution
of simulations (68, 95, 99 % quantiles in red) for the number of LGAs reporting at least 1 case in a given time period. f Data (blue) and score-weighted
distribution of simulations (68, 95, 99 % quantiles in red) for distribution of annual case counts among the 44 LGAs
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applied to the question of elimination probability given a
case-free period [5–8, 51], and this model is used to ad-
dress the same question.
The calibration parameter space from the 2003–2009
calibration is resampled for each simulation, with the
priors constricted to reflect the regions of high score in
Fig. 4. At this stage, the fitting timeframe is extended to
include all data until the most recently observed WPV1
case, and the simulation timeframe is extended to 2020.
Importation pressure from other states in northern
Nigeria is added to the model because Kano state under-
went a period of 20 months in 2009–2010 without a sin-
gle WPV1-positive paralysis case. This is a low-
probability event in this model and indicates the possi-
bility of a local elimination followed by reimportation.
Increasing campaign coverage over time is also added
to the model for this investigation, as the available data
on campaign coverage in Kano indicates that campaign
coverage improved in the late 2000s and into the 2010s
(lot quality assurance sampling (LQAS) data, provided
by the Nigerian WHO). In this exploration, campaign
coverage is assumed to increase linearly with time, be-
ginning at some time between Jan 1, 2005 and Jan 1,
2010. After the last campaign in the historical and
planned campaign calendar (Dec. 2015), campaigns are
assumed to use bOPV or mOPV1, with campaigns oc-
curring at a constant rate of 9/year.
Finally, the scale-free fitting utilized in calibration is not
appropriate for addressing the question of pathogen elim-
ination, as the size of the mixing population and the case-
to-infection ratio affect how long infection can silently
transmit. Therefore, the simulated population is reduced
to match the scale of the simulated infections with the ob-
served paralysis data at a case-to-infection ratio of 1:200.
The final simulated population is ~284000 in Mar 2006,
compared to the census population of 0–5 year olds of 1.8
million in the same year. Figure 7 demonstrates that the
quality of the calibration fits remains comparable to the
larger population simulations.
Results and discussion
The probability that WPV1 has been eradicated at day t
(i.e., the number of infected I(t) = 0 at day t), given that
the cumulative number of cases observed Nc(t) since the
last case is 0, is:
Perad tð Þ ¼ P I tð Þ ¼ 0jNc tð Þ ¼ 0ð Þ
¼ P Nc tð Þ ¼ 0 jI tð Þ ¼ 0ð Þ P I tð Þ ¼ 0ð Þ
P Nc tð Þ ¼ 0ð Þ
The probability of observing 0 cumulative cases is a bi-
nomial draw from the cumulative number of infections
Ic(t), and P(I(t) = 0) is an indicator function that is either
0 or 1 for each simulation and time point.
Perad tð Þ ¼ P Nc tð Þ ¼ 0 jI tð Þ ¼ 0ð ÞP Nc tð Þ ¼ 0ð Þ
¼
X
sims j I tð Þ¼0f g Bin 0jIc tð Þ; :005ð ÞX
all simsf gBin 0jIc tð Þ; :005ð Þ
A total of 16,350 simulations were performed, of
which 8113 survive until the time of the most recently
observed case. Figure 6 presents the probability of elim-
ination vs. time since the last case. One year out from
the last case, this model predicts a 91 % probability of
elimination, which rises to nearly 99 % 2 years out.
Figure 7 presents a selection of slices in the score
space and comparisons of simulations to data; Fig. 7(a)
presents the log-score in the space of the migration rate
scaling and the coefficient of variation of campaign
coverage. A comparison with Fig. 4 reveals that includ-
ing the years from 2009–2014 and the rise in campaign
coverage over time allows for stronger constraints on
this heterogeneity; the most likely values are quite high,
which allows local eliminations in the most well covered
Fig. 5 Histogram of unscaled outbound migration rates by node.
The high-score region shown in Fig. 4 centers around a scaling
factor of -6, indicating expected migration rates for most nodes
at ~0.1 per person per day
Fig. 6 Estimated probability of WPV1 elimination given 0 cases
observed since the last confirmed WPV1 case (Jul 24, 2014 in Kano state)
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LGAs but continued circulation in the set of poorly cov-
ered LGAs. The model fits best when campaign coverage
begins to increase sometime between 2006 and 2008,
with quite rapid increases of 50–100 % per year. The in-
crease in coverage, as implemented, is relative to the
“base” coverage, which ranges from 10–15 %. The best-
fit absolute rates of coverage increase can be estimated
from Fig. 7(c) and range from about 5 to 15 % additional
absolute coverage (vaccine efficacy remains constant)
per year.
Figure 8 provides a more detailed illustration of the
fraction of susceptibles who are successfully immunized
in each SIA round over time. The model predicts quite
low values of immunization within this population
throughout the early-mid 2000s. These rates are suffi-
cient to drive the system into sharp peaks of 2-year peri-
odicity, but the calibrated immunization rate rises
rapidly through the late 2000s to match the much lower
case counts of 2010–2015. A portion of the posterior
distribution of the statewide rate exceeds 20 % beginning
in 2014, indicating that the chosen values for take rate
may have been too low (as campaign coverage should
not exceed 100 %).
A number of features of this model may contribute to an
overall optimistic picture of elimination, however. The
campaign coverage is assumed to have been rising over
time for approximately the past 10 years, which allows the
model to fit the dramatically reduced incidence from
2010–2015 compared to the previous decade, and this in-
creasing coverage is assumed to continue into the future.
Furthermore, future modeled campaigns were assumed to
be mOPV1 or bOPV, but as the WPV1 case-free period
grows, the use of tOPV, which is less effective at providing
immunity against Type 1 [13], has increased correspond-
ingly as the focus shifts to eliminating circulating vaccine-
derived poliovirus Type 2 (cVDPV2). The closed nature of
the modeled population also does not admit the possibility
of exportation to at-risk populations connected to that of
Kano state; even if transmission is currently declining to-
wards elimination, exportation to outside populations could
provide a reservoir for re-establishment. Time-varying or
LGA-specific levels of routine immunization are not
accounted for in this model; nor is the co-administration of
inactivated polio vaccine (IPV) with OPV.
The probability of polio elimination given a case-free
period has been addressed in previous work, in other
Fig. 7 Results of date of elimination simulations. a Log-score vs. the scaling factor in the migration rate model and the LGA-level coefficient of
variation in campaign coverage. b Log-score vs. the time at which campaign coverage begins to increase, and the relative annual rate of increase.
c Log-score vs. the base campaign and the relative annual rate of coverage increase. d Data (blue) and score-weighted distribution of simulations
(68, 95, 99 % quantiles in red) for age distribution of paralysis cases. e Data (blue) and score-weighted distribution of simulations (68, 95, 99 %
quantiles in red) for time series of case counts. f Data (blue) and score-weighted distribution of simulations (68, 95, 99 % quantiles in red) for the
number of LGAs reporting at least 1 case in a given time period
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contexts [8, 51] and in Nigeria [5–7]. The results of this
model are similar to other recently published results
considering the Nigerian context, which are derived
from models differing widely in structure from the
present model. Of these models, the present model
uniquely features spatially structured metapopulations
with heterogeneous immunization coverage, which admits
certain phenomena of interest in the near-elimination re-
gime – localization of transmission chains and the possi-
bility of escape from an infected region to another region
that is not experiencing local transmission. The calibration
procedure presented is also unique among the Nigeria
models in methodology and in the data targets. The con-
fluence of results from multiple models provides some
confidence that the optimistic biases discussed above do
not drive this result, and provide support to the WHO’s
recent removal of Nigeria from the list of polio-endemic
countries [4].
Conclusions
The model predicts that at the time of writing, October
2015, the lack of any cases since July 24, 2014 [3] indi-
cates a probability of 91 % that WPV1 has been elimi-
nated from Kano state. The other states in Nigeria have
experienced even longer case-free periods (the only
other state with a WPV1 case in 2014 was Yobe, on
April 19, 2014), and as Nigeria is the last remaining
country in Africa to experience endemic transmission of
WPV1, this probability can be interpreted as an upper
bound on the probability that endemic transmission of
WPV1 has been interrupted continent-wide. If another
year passes without any observed WPV1 paralysis cases,
this model indicates a 99 % chance of elimination.
The model assumes that frequent SIAs with high cover-
age continue to take place in Kano state through the end of
the simulation period, and though these results are optimis-
tic that WPV1 transmission in Kano has been or will soon
be interrupted, these results do not provide support for any
reduction in vaccination activities in the immediate future.
The results indicate that it is important for the polio pro-
gram to maintain vigilance in surveillance and vaccination
activities to prevent WPV1 resurgence through the WHO’s
3-year eradication certification period.
Added June 2016: On 23 March 2016, a cVDPV2-
positive environmental sample was isolated in the
Maiduguri district of Borno state, Nigeria, and determined
to be genetically linked to a strain last observed in May
2014 [52]. As calibration of the presented model focused
exclusively on WPV1, it cannot be directly applied to si-
lent circulation of cVDPV2; investigations of silent
cVDPV2 circulation can be found in [6, 7]. Both refer-
ences find that long-term silent circulation of Type 2 is
more likely than Type 1, even with perfect AFP surveil-
lance. The difference in case-to-infection ratios (approxi-
mately 1:200 for Type 1, 1:1900 for Type 2 [29]) likely
accounts for much of the difference in silent circulation of
the two serotypes, but the appearance of this environmen-
tal sample demonstrates that silent circulation remains a
major concern in certifying global poliovirus eradication,
particularly after the April 2016 worldwide withdrawal of
OPV2 [53].
Added August 2016: Since preparation of this manu-
script, multiple persons infected with WPV1 were dis-
covered in areas of Borno state previously inaccessible to
programmatic activities due to violence and instability.
One WPV1-positive paralysis case was found along with
Fig. 8 a 95 % quantiles of the score-weighted distributions of (red) statewide mean SIA coverage over time as estimated in calibration of the
presented model; (orange) statewide mean SIA coverage over time as estimated using a model based on non-polio acute flaccid paralysis
(NP-AFP); (black) statewide mean SIA coverage as estimated from lot quality assurance sampling (data provided by Nigerian WHO); (blue)
statewide mean vaccine-derived immunity in 0–5 year olds from the presented model; (green) statewide mean vaccine-derived immunity
in 0–5 year olds from a statistical model deriving campaign coverage from the reported vaccine dose histories of non-polio acute flaccid paralysis
cases. The NP-AFP immunity model is an extension of that presented in [56] (publication detailing newer model is in preparation). b Illustration of
historical campaign calendar in Kano state
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multiple WPV1-positive healthy close contacts, and a sec-
ond paralysis case that was WPV1-negative was found to
have a WPV1-positive close contact [54]. Genetic sequen-
cing indicates a period of approximately 5 years between
the virus causing these infections and the most recent
known related infection [55]. These observations of WPV1
follow a recent discovery of a cVDPV2 circulating silently
for nearly 2 years. These discoveries emphasize the neces-
sity of high-quality surveillance during the polio endgame
and certification process. Many other regions of Borno re-
main inaccessible to surveillance, limiting knowledge about
the extent of the WPV1 transmission within the state.
This approximately 5 years of silent circulation may call
into question the presented results. The model’s predicted
probability of elimination vs. time since the last paralytic
case depends on two crucial assumptions: that SIAs con-
tinue to take place after the last observed paralysis case,
and that surveillance for new paralytic cases is of high qual-
ity. Neither of these assumptions hold in the inaccessible
areas of Borno. This and other models approaching the
question all find 5 years of circulation without generating a
new paralysis case extremely unlikely [5–8], indicating a
probable surveillance failure throughout the inaccessible re-
gions of Borno. These cases, along with the cVDPV2 previ-
ously observed in Borno, highlight the existential risk that
inaccessible populations present to polio eradication.
Additional file
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